Skip to main content
OSTI.GOVU.S. Department of Energy Office of Scientific and Technical Information
U.S. Department of Energy
Office of Scientific and Technical Information
 

Discovery of BMS-986260, a Potent, Selective, and Orally Bioavailable TGFβR1 Inhibitor as an Immuno-oncology Agent

Journal Article · · ACS Medicinal Chemistry Letters
 [1];  [1];  [2];  [1];  [2];  [1];  [1];  [1];  [1];  [1];  [2];  [2];  [2];  [2];  [1];  [1];  [1];  [1];  [1];  [1] more »;  [1];  [2];  [2];  [2];  [1];  [3];  [3];  [3];  [1];  [1];  [1];  [1] « less
  1. Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
  2. Biocon Bristol-Myers Squibb R & D Center, Biocon Park, Jigani Link Road, Bangalore, KA 560099, India
  3. Rigel Pharmaceuticals, Inc., 1180 Veterans Boulevard, South San Francisco, California 94080, United States
+ Show Author Affiliations
Abstract not provided
Research Organization:
Advanced Photon Source (APS), Argonne National Laboratory (ANL), Argonne, IL (US)
Sponsoring Organization:
INDUSTRY
OSTI ID:
1604185
Journal Information:
ACS Medicinal Chemistry Letters, Journal Name: ACS Medicinal Chemistry Letters Journal Issue: 2 Vol. 11; ISSN 1948-5875
Publisher:
American Chemical Society (ACS)
Country of Publication:
United States
Language:
ENGLISH

Similar Records

Discovery of chiral dihydropyridopyrimidinones as potent, selective and orally bioavailable inhibitors of AKT
Journal Article · Fri Jun 01 00:00:00 EDT 2018 · Bioorganic and Medicinal Chemistry Letters · OSTI ID:1474162
Discovery of 4-Azaindole Inhibitors of TGFβRI as Immuno-oncology Agents
Journal Article · Fri Jul 26 00:00:00 EDT 2019 · ACS Medicinal Chemistry Letters · OSTI ID:1545843
Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development
Journal Article · Tue Feb 04 23:00:00 EST 2014 · Journal of Medicinal Chemistry · OSTI ID:1497139

Related Subjects